OptiBiotix Health (AIM:OPTI), an AIM-listed life sciences company developing products that target hunger, food cravings and the gut microbiome, said Holland & Barrett has launched a weight management product containing its SlimBiome formulation under a new own-brand called FORMI.
Holland & Barrett, which operates more than 1,600 stores across 19 countries including over 700 in the UK, signed a three-year non-exclusive trademark licence in December granting it rights to use the SlimBiome and LeanBiome marks on new products.
The FORMI launch builds on that agreement and follows Holland & Barrett's May partnership with online pharmacy Phlo, which gives customers access to clinical weight management services including GLP-1 anti-obesity medicines alongside its nutrition and wellness range.
OptiBiotix points to research suggesting people who stop GLP-1 treatment can regain weight faster than those on traditional diet programmes, a dynamic it says is fuelling demand for complementary, non-drug products.
The global market for GLP-1 support supplements is estimated at approximately $1.8 billion in 2025, forecast to reach $8.9 billion by 2034.
"We are particularly pleased to see H&B incorporating SlimBiome into its new FORMI own-brand range," said Stephen O'Hara, chief executive of OptiBiotix Health, adding that the launch "provides an opportunity for SlimBiome to participate in the expansion of H&B's own-brand weight management portfolio."
News Intelligence what this means for the company
Holland & Barrett has launched FORMI, an own-brand weight management product built around OptiBiotix's SlimBiome formulation, operationalizing the three-year non-exclusive trademark licence signed in December. The move positions OptiBiotix to capture revenue from a retailer operating over 1,600 stores across 19 countries as demand for GLP-1 support supplements—estimated at $1.8 billion globally in 2025—expands, particularly among customers who discontinue prescription anti-obesity drugs.
This is the first commercial deployment of OptiBiotix's SlimBiome under the December licence agreement, validating the formulation's appeal to a major retail distributor and converting a licensing right into shelf presence. The timing aligns with Holland & Barrett's May partnership with Phlo to offer GLP-1 medicines, suggesting OptiBiotix's complementary positioning in weight management may capture a meaningful share of customer journeys as the GLP-1 market scales.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
